Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3414582 | Microbes and Infection | 2016 | 5 Pages |
Abstract
Currently, there is no specific antiviral therapy for HPV infection. We conducted a randomized open-label clinical trial of JB01-BD, an anti-HPV biological dressing from Shanxi Jinbo Pharmaceutical Co., Ltd., China, for treatment of HPV infection. Seventy-seven women with cervical infection by high-risk HPV were randomly divided into a treatment group and a non-treatment group. After treatment, about 60.5% (23/38) of HPV-positive women in the treatment group became HPV-negative compared with 13.5% (5/37) of women in the non-treatment group becoming HPV-negative (P < 0.001). These data suggest that JB01-BD is an effective topical biological agent for the treatment of cervical HPV infection.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Xuetao Guo, Lixia Qiu, Yue Wang, Yonghong Wang, Qian Wang, Lei Song, Yali Li, Ke Huang, Xinxin Du, Wensheng Fan, Shufang Jiang, Qianqing Wang, Haoyang Li, Yi Yang, Yuanguang Meng, Yun Zhu, Lu Lu, Shibo Jiang,